A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 32
- Population
- ALL · 50 Years
- Duration
- 2017-08-29 to 2019-01-16
- Intervention
- GB-102; Aflibercept
- Comparator
- Active Comparator: Phase 2 - Aflibercept
- Outcomes measured
- Phase 1: Occurrence of ocular and nonocular adverse events (AEs) — 8 months; Phase 2: Change from baseline in best corrected visual acuity by ETDRS — Baseline, Month 9; Phase 1: Change from baseline in BCVA by ETDRS — 8 months; Phase 1: Change from baseline in sub-retinal thickness — 8 months; Phase 1: Change from baseline in retinal fluid by SD-OCT — 8 months; Phase 1: Change from baseline in total lesion area by FA/CFP — 8 months; Phase 1: Change from baseline in CNV lesion area by FA/CFP — 8 months; Phase 1: Change from baseline in fluorescein leakage area by FA/CFP — 8 months; Phase 1: Rescue medication — 8 months; Phase 1: Systemic exposure to sunitinib measured in plasma level — 8 months; Phase 1: Change from baseline in sub retinal hyper reflective material (SHRM) height — 8 months; Phase 2: Proportion of subjects with absence of retinal fluid by SD-OCT — 12 months; Phase 2: Proportion of subjects with < 15 BCVA letter loss by ETDRS — 12 months; Phase 2: Proportion of subjects with ≥ 15 BCVA letters gained by ETDRS — 12 months; Phase 2: Occurrence of ocular and nonocular adverse events (AEs) — 12 months; Phase 2: Change from baseline in BCVA by ETDRS — 12 months; Phase 2: Systemic exposure to sunitinib measured in plasma level — 12 months; Phase 2: Change from baseline in sub-retinal thickness — 12 months; Phase 2: Rescue medication — 12 months
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.